ZMYM4

Across TCGA pan-cancer cohorts, ZMYM4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZMYM4 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZMYM4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZMYM4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where ZMYM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.107	1.000	.010	42	view →
CCRCC	DFS	Quartile	II,III,IV	0.067	0.978	.024	12	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LUAD	OS	Median	III,IV	0.665	0.237	.020	5	view →
GBM	DFS	Quartile	All	0.447	0.239	.016	3	view →
LSCC	DFS	Median	All	1.000	0.905	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZMYM4–HNSC (DFS)

Open the HNSC breakdown →